Danaher Boosts Full-Year EPS Guidance on Strong Q2 Earnings and Masimo Acquisition — Danaher Corporation

Event summary

Danaher reported Q2 2026 revenues of $6.3B, up 5.5% YoY, with non-GAAP core revenue growth of 3.0%.
Net earnings rose 60% YoY to $870M, or $1.23 per diluted share.
Adjusted EPS grew 8.0% YoY to $1.94, driven by strong Life Sciences performance and bioprocessing orders growing mid-teens.
Danaher raised full-year adjusted EPS guidance to $8.45–$8.60 from $8.35–$8.55 due to better-than-expected Q2 results and the early completion of the Masimo acquisition.

The big picture

Danaher's strong Q2 performance and raised guidance reflect its strategic focus on life sciences and diagnostics innovation. The completion of the Masimo acquisition and pending StatLab deal underscore its commitment to expanding its portfolio in high-growth segments. The company's ability to navigate project timing issues and sustain operational excellence will be critical as it positions itself for long-term shareholder value creation.

What we're watching

Integration Success: How Danaher will integrate Masimo and StatLab to achieve expected synergies and growth.
Market Recovery: Whether the continued end-market recovery will sustain mid-single-digit core revenue growth exiting 2026.
Operational Execution: The pace at which Danaher can maintain high-single-digits adjusted EPS growth amid bioprocessing project timing challenges.